Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347684 | 0.87 | MEN1 (0.57) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL20468309 | 0.87 | MEN1 (0.57) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL4610835 | 0.84 | MEN1 (0.53) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL22052987 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL20417941 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL19739064 | 0.83 | MEN1 (0.52) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL5784665 | 0.81 | MEN1 (0.64) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL10952739 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL141336 | 0.78 | MEN1 (0.73) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL21504125 | 0.78 | MEN1 (0.50) | MEN1KMT2ATDP1MAOACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | MEN1 756/4885KMT2A 3471/4885TDP1 803/4885 |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | MEN1 4193/4885KMT2A 1124/4885TDP1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.